NCT05119296View on ClinicalTrials.gov

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Thyroid Cancer
Interventions
DRUG

Pembrolizumab (Keytruda)

Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death

Trial Locations (1)

94305

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Stanford University

OTHER